A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 26 Feb 2018 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 According to an Esperion Therapeutics media release, the company expects top-line results in Mar 2018.
- 06 Nov 2017 Planned End Date changed from 31 Mar 2018 to 30 Jun 2018.